Products for Out-Licensing

Products Out-Licensing

NAL develops novel dosage forms and proprietary drug delivery systems based on Company’s captive Drug Delivery System (“DDS”) technologies. NAL expects to partner with pharmaceutical companies for the development and commercialization of the NAL products in global markets.

The partial listing of NAL’s products is outlined below. As we have not disclosed the complete list of our proprietary DDS products under development, please write to us at to know more about NAL’s products and partnering opportunities.

Central Nervous System
Products Marketed or Under Development (Partial Listing)
Proposed US Filing
NAL8812 Donepezil 3-Day Patch for Alzheimer’s Disease
505(b)(2) NDA
NAL8817 Donepezil ODF for Alzheimer Disease
505(b)(2) NDA
NAL8823 Rivastigmine 1-Day Patch for Alzheimer’s Disease
NAL8776 Rotigotine Patch for Parkinson Disease
NAL2516 Selegiline 1-Day Patch for Parkinson's Disease
NAL2522 Risperidone Microsphere Injection for Schizophrenia